Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06974916 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

EMBRACE Tremor BiFUS

StatusRecruiting
PhaseNot applicable
SponsorInSightec
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 11 months later Jul 2026 → Jul 2027
See other at-risk trials from InSightec

Record History

  1. Primary completion pushed from Jul 2026 to Jul 2027v14
  2. Site details revised at 1 of 13 sitesv13
  3. Trial sites expanded: 8 → 13 locationsv12
  4. Completion pushed from Jan 2028 to Mar 2028 Eligibility criteria expanded, about 8 wordsv11 Show 1 more changeShow less
    • Eligibility criteria expanded, about 8 words

    See this version in full on ClinicalTrials.gov ↗

  5. Study sites: 6 to 8v10
Show 8 earlier versionsHide 8 earlier versions
  1. Site details revised at 1 of 6 sitesv9
  2. Re-verified, no change to tracked fieldsv8
  3. Primary completion date: Dec 2026 to Jul 2026 Completion date: Apr 2027 to Jan 2028v7 Show 1 more changeShow less
    • Completion date: Apr 2027 to Jan 2028
  4. Re-verified, no change to tracked fieldsv6
  5. Study sites: 4 to 6v5
  6. Site details revised at 2 of 4 sitesv4
  7. Start date: Mar 11, 2025 to Apr 22, 2025v3
  8. Primary endpoint revised Secondary endpoints revised (9)v2 Show 1 more changeShow less
    • Secondary endpoints revised (9)

    See this version in full on ClinicalTrials.gov ↗

  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
InSightec
42 trials monitored
See 1 trial at risk
This is a post-market (Phase IV) randomized, controlled, blinded, multicenter study with the aim to determine the added value of staged bilateral Exablate thalamotomy compared to a group of patients on previous unilateral treatment combined with local standard medical treatment.
Trial Details
NCT Number NCT06974916
Lead Sponsor InSightec
Conditions Essential Tremor
Enrollment 100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov